A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Inclusion Criteria: * Patients with Acute Coronary Syndromes * Patients who are taking ticagrelor and ASA daily(75-150mg), or Patients who are taking ticagrelor only(In the case that the patients have contraindication with ASA. Contraindication should be recorded in accordance with local PI on CRFs) * Patients who have signed the Data release consent form prior to enrollment in this surveillance Exclusion Criteria: * Patients with hypersensitivity to ingredients of this drug or with moderate or severe hepatic impairment or with medical history of intracranial hemorrhage * Patients with pathological hemorrhage at the time of administration * Patients being administrated strong CYP3A4 inhibitors